Enodia Therapeutics signed a research collaboration and licensing agreement with Pfizer targeting small-molecule inhibitors of the Sec61 translocon. Enodia will lead discovery activities to screen and optimize Sec61 inhibitor candidates across multiple collaboration targets, while Pfizer will control clinical, regulatory, manufacturing, and commercial execution after the collaboration term. Enodia said it will receive an upfront payment and milestone eligibility, with total potential value exceeding $500 million, plus tiered royalties on net sales. The company’s Sec61 program is framed as selectively modulating protein translocation to inhibit disease-driving proteins earlier in the biology pipeline. This matters for industry because it validates Sec61 as a tractable drug target for translational development and demonstrates how big pharma continues to expand targeted protein modulation beyond established degradation modalities. It also reinforces Enodia’s strategy of platform-led licensing and multi-program discovery collaboration.